• Akebia Therapeutics reported topline VOCAL trial results showing three-times-weekly vadadustat met its primary goal of non-inferiority to ESA treatment in maintaining hemoglobin.
• The trial enrolled 353 patients with kidney disease-related anemia receiving in-center hemodialysis; serious treatment-emergent adverse event rates were similar between treatments.
• The three-times-weekly regimen remains investigational. Vafseo, the drug’s brand name, is approved for once-daily use.
• FDA approval came in March 2024 for adults receiving dialysis for at least three months; US availability began in January 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870884) on November 05, 2026, and is solely responsible for the information contained therein.